POP Biotechnologies Awarded $2.46M NIH Grant for Alzheimer's Immunotherapy
Innovative 'Mosaic' Active Immunotherapy to Target Alzheimer's Disease
Buffalo, NY , Oct. 01, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mosaic” active immunotherapy against Alzheimer’s disease (AD).
Illustration of concept immunotherapy displaying Aβ and phospho-tau targets in a mosaic-like fashion on the surface of nanoparticles.
The project, “Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes,” leverages POP BIO’s proprietary spontaneous nanoliposome antigen particle (SNAP) platform to develop an active immunotherapy with multiple amyloid-beta (Aβ) and phospho-tau targets simultaneously.
The technology is based on displaying the Aβ and phospho-tau targets in a mosaic-like fashion on the surface of nanoparticles. The body’s own immune response then generates antibodies that aim to neutralize these pathogenic targets.
The award is a collaborative effort led by POP BIO and Dr. Chunling Dai, an expert in Alzheimer’s disease at the New York State Institute for Basic Research in Developmental Disabilities (Staten Island, NY), and investigators at the University of Puerto Rico.
AD is a progressive neurodegenerative disorder characterized by brain accumulation of Aβ plaques and phospho-tau neurofibrillary tangles. Due to the complexity of AD pathogenesis, a multipronged approach targeting both proteins may overcome limitations of current treatments. AD affects over 55 million people worldwide, representing an estimated $19.3B market opportunity with 13% CAGR.
Under the Phase II Small Business Technology Transfer (STTR) NIH grant, POP BIO will scale, characterize, and validate the immunotherapy candidate with the goal of advancing toward human trials. “This award provides significant validation of our approach and great opportunity to advance our mosaic SNAP active immunotherapy,” said Dr. Wei-Chiao Huang, Director of Vaccine Development at POP Biotechnologies.
Dr. Dai, co-investigator at the Institute for Basic Research, said “By targeting multiple components of Alzheimer’s pathology at once, we aim to achieve a level of protection that is not possible with traditional single-target immunotherapies.”
The Alzheimer’s immunotherapy program is part of a broader initiative also involving EuPOP Life Sciences, a joint venture between POP BIO and EuBiologics Co., Ltd., a South Korea-based global vaccine leader. These partners are advancing development of the AD vaccine, leveraging POP BIO’s SNAP nanoliposome platform and EuBiologics’ complementary vaccine adjuvant technology.
About POP Biotechnologies, Inc. (POP BIO)
POP Biotechnologies, Inc. is a privately held biotechnology company in Buffalo, NY, focused on developing novel therapeutics and vaccines employing its proprietary porphyrin-phospholipid (PoP) and SNAP liposome technologies.
About POP BIO SNAP(TM)
POP BIO’s Spontaneous Nanoliposome Antigen Particle (SNAP) technology enables the rapid manufacture of highly immunogenic particle-based vaccines and immunotherapies for infectious diseases, cancer, AD, and other conditions. SNAP has undergone substantial validation in humans, including the successful completion of a Phase 3 clinical trial for a COVID-19 vaccine and ongoing Phase 1 trials in RSV and shingles (HZV). POP BIO holds exclusive license to the underlying IP for the SNAP platform from The Research Foundation for The State University of New York Research Foundation (RFSUNY), which was developed by company co-founder Dr. Jonathan Lovell at SUNY Buffalo.
About EuPOP Life Sciences
EuPOP Life Sciences is a Buffalo, NY-based joint venture between POP Biotechnologies and EuBiologics Co., Ltd., formed to advance and globally commercialize potent vaccines using POP BIO’s SNAP liposome platform and EuBiologics’ proprietary adjuvant, EcML. EuPOP’s research and development operations in Buffalo leverage the complementary strengths of its parent companies to drive a pipeline of next-generation vaccines – including candidates for RSV, shingles, and Alzheimer’s disease – with a mandate to serve patients worldwide. For more information, visit www.eupop.life.
Research reported in this press release was supported by the National Institute on Aging of the National Institutes of Health under Award Number 2R42AG082620-03. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Press inquiries
POP Biotechnologies
https://pop.bio
Jonathan Smyth, Esq.
jrsmyth@pop.bio
3152200087
Baird Research Park, Suite 221, 1576 Sweet Home Road, Buffalo, NY 14228-2710
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
